Lamotrigine
Lamictal, Lamotrigine (lamotrigine) is a small molecule pharmaceutical. Lamotrigine was first approved as Lamictal on 1994-12-27. It is used to treat bipolar disorder, epilepsy, lennox gastaut syndrome, mood disorders, and partial epilepsies amongst others in the USA. It is known to target sodium channel protein type 2 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Lamictal (generic drugs available since 2009-01-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lamotrigine, Lamictal Xr, Glaxosmithkline Llc | |||
| 8637512 | 2028-06-14 | DP | |
HCPCS
No data
Clinical
Clinical Trials
224 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 11 | 4 | 10 | 17 | 23 | 63 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 7 | 4 | 16 | 18 | 14 | 57 |
| Healthy volunteers/patients | — | — | — | 19 | — | — | 1 | 2 | 22 |
| Depression | D003863 | — | F33.9 | — | — | 2 | 3 | 2 | 7 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 4 | 3 | — | 7 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 3 | 1 | 2 | 6 |
| Psychotic disorders | D011618 | — | F20.81 | — | 1 | — | 1 | 1 | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 1 | 1 | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | 1 | 1 | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | 2 | 3 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | HP_0002069 | G40.4 | 2 | 1 | 2 | — | 2 | 6 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | 1 | — | 1 | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | — | 2 |
| Absence epilepsy | D004832 | HP_0011147 | G40.A | — | — | 2 | — | — | 2 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 1 | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Ketogenic diet | D055423 | — | — | — | — | 1 | — | — | 1 |
| Neurofibromatosis 1 | D009456 | — | Q85.01 | — | 1 | 1 | — | — | 1 |
| Myotonic disorders | D020967 | Orphanet_606 | G71.1 | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
| Vertigo | D014717 | — | H81.39 | — | 2 | — | — | — | 2 |
| Meniere disease | D008575 | EFO_0006862 | H81.0 | — | 2 | — | — | — | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | — | 1 |
| Brain injuries | D001930 | — | S06.9 | 1 | 1 | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Neurotic disorders | D009497 | — | F48.9 | — | 1 | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 4 | — | — | — | — | 4 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 1 | 1 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 1 | 1 |
| Drug hypersensitivity syndrome | D063926 | EFO_1002004 | D72.12 | — | — | — | — | 1 | 1 |
| Emotions | D004644 | — | — | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | — | 1 | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 1 | 1 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | — | — | — | 1 | 1 |
| Facial nerve diseases | D005155 | — | G51 | — | — | — | — | 1 | 1 |
| Cognition disorders | D003072 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lamotrigine |
| INN | lamotrigine |
| Description | Lamotrigine is a member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. It has a role as an anticonvulsant, an antimanic drug, an antidepressant, a non-narcotic analgesic, a calcium channel blocker, an excitatory amino acid antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, an environmental contaminant, a xenobiotic and a geroprotector. It is a member of 1,2,4-triazines, a primary arylamine and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | sodium channel blockers, signal transduction modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1 |
Identifiers
| PDB | — |
| CAS-ID | 84057-84-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL741 |
| ChEBI ID | 6367 |
| PubChem CID | 3878 |
| DrugBank | DB00555 |
| UNII ID | U3H27498KS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
HBA, NAC2, SCN2A1, SCN2A2
NCBI Gene ID
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lamotrigine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,604 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
65,198 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use